Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder
Neuropsychiatric Disease and Treatment · 2011-05 · 303
DOI: 10.2147/ndt.s18333 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuropsychiatric Disease and Treatment, 2011-05. Verfasst von Robert M Berman und 8 weiteren Autor:innen. Beteiligte Einrichtung: Neuroscience Global Clinical Research Bristol-Myers Squibb, Wallingford, CT, USA;. Die Arbeit wurde bisher 36-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Neuroscience Global Clinical Research Bristol-Myers Squibb, Wallingford, CT, USA;
Zitieren
APA
Berman, R. M., Thase, M. E., Trivedi, M. H., Hazel, J. A., Marler, S. V., McQuade, R. D., Carson, W., Baker, R. A., & Marcus, R. N. (2011). Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder. Neuropsychiatric Disease and Treatment, 303. https://doi.org/10.2147/ndt.s18333
Vancouver
Berman RM, Thase ME, Trivedi MH, Hazel JA, Marler SV, McQuade RD, et al. Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder. Neuropsychiatric Disease and Treatment. 2011:303. doi:10.2147/ndt.s18333
BibTeX
@article{Berman2011,
author = {Berman, Robert M and Thase, Michael E and Trivedi, Madhukar H and Hazel, James A and Marler, Sabrina Vogel and McQuade, Robert D and Carson, William and Baker, Ross A and Marcus, Ronald N},
title = {Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder},
journal = {Neuropsychiatric Disease and Treatment},
year = {2011},
pages = {303},
doi = {10.2147/ndt.s18333}
}
EUVIMED